Pure Global AI
NCT06419413Recruiting

A Translational Study to Describe Clinical Characteristics, Biomarkers and to Identify Phenotypes and Endotypes Associated With Differential Outcomes in Chinese Population

A Transnational Study to Describe Asthma Patient Clinical Characteristics, Treatment Patterns, Biomarkers and to Identify Phenotypes and Endotypes Associated With Differential Outcomes That May Support Future Development of Personalized Treatment Strategies in Chinese Population
AstraZenecaClinicalTrials.gov
Verified
Study focus
Disease/Condition
Asthma
Study type
Observational
Sponsor & location
Primary sponsor
AstraZeneca
Location
Chengdu,Beijing,Changsha,Dongguan,Foshan,Guangzhou,Hainan,Hohhot,Huizhou,Kunmin,Nanjing,Nanning,Shanghai,Shenyang,Taiyuan,Wenzhou,Wuhan,Xi'an,Xuzhou,Zhanjiang,Zhaoqing, China
Timeline & enrollment
Phase
N/A
Start date
Jan 18, 2024
End date
Oct 20, 2026
Enrollment
1000 participants
Primary outcome

Descriptive summary of demographic and subject characteristic, clinical characteristics and functional deliverables.,Descriptive summary of biomarker level.,Statistical clustering of key biomarkers.

Summary

A Translational Study to Describe Asthma Patient Clinical Characteristics, Treatment
 Patterns, Biomarkers and to Identify Phenotypes and Endotypes associated with Differential
 Outcomes that may Support Future Development of Personalised Treatment Strategies in Chinese
 Population

ICD-10 classifications
AsthmaAsthma, unspecifiedNonallergic asthmaMixed asthmaPredominantly allergic asthma
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06419413
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06419413 through Pure Global AI's free database. This phase not specified trial is sponsored by AstraZeneca and is currently Recruiting. The study focuses on Asthma. Target enrollment is 1000 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.